US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
WEB5 hours ago · Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA) and Regeneron's (REGN.O) blockbuster drug Dupixent for patients with a chronic lung disease commonly known ...
FDA, after delay, clears Regeneron and Sanofi drug for COPD
WEB19 hours ago · European regulators approved Dupixent for COPD in July, but Regeneron and Sanofi have had to wait longer in the U.S., where the FDA requested additional efficacy data from the two trials. Over that time, a potential new competitor has emerged in GSK’s Nucala, which the FDA rejected in 2018 but earlier this month succeeded in a Phase 3 trial.
Sanofi blockbuster drug wins clearance in US for lung disease
WEB3 hours ago · Bloomberg. Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after a similar decision by European regulators. The US Food ...
Latest Sanofi Press Releases and News | Sanofi
WEBSep 11, 2024 · Stay informed with the latest Sanofi press releases and news updates. Discover new developments in healthcare and pharmaceuticals with Sanofi.
Press Release: Dupixent approved in the US as the first-ever ... - Sanofi
WEBSep 27, 2013 · Paul Hudson Chief Executive Officer at Sanofi “Dupixent has already shown it can revolutionize the treatment paradigm of many diseases driven in part by type 2 inflammation with high unmet medical needs, with one million patients being treated globally across all currently approved indications. With today’s approval, Dupixent once again ...
Sanofi pushes ahead with €20bn consumer healthcare spin-off
WEBJun 2, 2024 · The move makes Sanofi the latest Big Pharma company to seek to separate low-margin, consumer businesses from divisions focused on innovative new medicines that offer higher returns.
Sanofi Pipeline Transformation to Accelerate Growth Driven by …
WEBDec 7, 2002 · Sanofi’s R&D will lead to a 50% increase in the number of Phase 3 studies between 2023 and 2025, creating the greatest pipeline momentum in Sanofi’s history. The company’s commitment to R&D will also support an expected 25 mid- to late-stage read-outs and up to 19 regulatory submissions for its pharma assets in the next two years.
Blockbuster Dupixent wins FDA approval for COPD - STAT
WEB5 hours ago · Sept. 27, 2024. West Coast Biotech & Life Sciences Reporter. Dupixent is already a blockbuster therapy for a range of immune-mediated diseases, but the Food and Drug Administration’s approval of ...
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's …
WEB5 hours ago · Sanofi recorded 10.72 billion euros ($11.94 billion) in sales for Dupixent in 2023, which includes Regeneron's share. Analysts on average expect Dupixent, by far Sanofi's best-selling drug, to ...
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's …
WEB5 hours ago · The logo of French drugmaker Sanofi is seen a the Sanofi Genzyme Polyclonals in Lyon. (Reuters) - The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug ...
Skip to content